CBAY News and Press, CymaBay Therapeutics Inc. From 09/21/23

AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation Data will be used to support post-marketing regulatory requirements for seladelpar’s accelerated approval pathway NEWARK, Calif., Sept. 21, 2023 (GLOBE NEWSWIR...

NEWARK, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the Cantor Global H...

NEWARK, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases with high unmet medical need, today announced the closing of its previously anno...

2023-09-12 17:37:00 ET The hot-streak biotech stock of the moment, CymaBay Therapeutics (NASDAQ: CBAY) , again rose in price on Tuesday. That extends the company's winning streak on the market following the impressive late-stage clinical results from a key investigative drug. The co...

2023-09-12 06:48:45 ET CymaBay Therapeutics ( NASDAQ: CBAY ) prices public offering of 12,551,080 common shares at $17.13 per share and 583,771 pre-funded warrants at $17.1299 per underlying share for total gross proceeds of ~$225M. The pre-funded warrant has an exercise ...

NEWARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases with high unmet medical need, today announced the pricing of its previously anno...

2023-09-11 18:31:59 ET For the third day in a row, shares of CymaBay Therapeutics (NASDAQ: CBAY) enjoyed a very healthy gain in price. That came on the announcement of a capital-raising effort by the company. Ultimately, CymaBay stock closed Monday more than 5% higher; by comparison...

2023-09-11 06:07:59 ET CymaBay Therapeutics ( NASDAQ: CBAY ) has commenced an underwritten public offering of an aggregate of $150M of its common stock and pre-funded warrants. The underwriters has a 30-day option to purchase up to an aggregate of an additional 15% of the shar...

NEWARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases with high unmet medical need, today announced that it has commenced an underwrit...

2023-09-10 06:05:05 ET Summary Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patients with primary biliary cholangitis. Positive results of the phase 3 RESPONSE study leads to additional data at an upcoming medical meeting and poss...